FindTrial
Sign In

Enadenotucirev

BIOLOGICAL4 trials

Sponsors

Akamis Bio, University of Oxford

Conditions

Colorectal CancerEpithelial TumorLocally Advanced Rectal CancerMetastatic Bladder CancerMetastatic Colorectal CancerRecurrent Platinum Resistant Ovarian CancerSolid Tumours of Epithelial OriginSquamous Cell Carcinoma of the Head and Neck

Phase 1

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
CompletedNCT02028117
Akamis BioRecurrent Platinum Resistant Ovarian Cancer
Start: 2014-06-30End: 2019-11-19Updated: 2021-05-13
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
CompletedNCT02028442
Akamis BioMetastatic Bladder Cancer, Metastatic Colorectal Cancer, Solid Tumours of Epithelial Origin
Start: 2012-09-20End: 2016-04-29Updated: 2020-03-12
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
CompletedNCT02636036
Akamis BioColorectal Cancer, Epithelial Tumor, Squamous Cell Carcinoma of the Head and Neck
Start: 2016-01-25End: 2021-10-08Updated: 2021-11-09
Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer
CompletedNCT03916510
University of OxfordLocally Advanced Rectal Cancer
Start: 2019-07-29End: 2023-02-24Updated: 2025-02-06

Related Papers

Abstract CT155: Phase 1b trial of NG-350A, a CD40 agonist antibody expressing adenoviral vector, in combination with chemoradiotherapy (CRT), in patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC): Initial results from the FORTRESS study
Cancer Research2026-04-17
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)
Journal for ImmunoTherapy of Cancer2023-04-0141 citations
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.
2023-03-106 citations
Safety and tolerability of T-SIGn vectors when administered using “flat” versus “low-high-high” (LHH) dosing regimens.
Journal of Clinical Oncology2022-06-01
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Journal for ImmunoTherapy of Cancer2021-12-0147 citations
342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study
Regular and Young Investigator Award Abstracts2021-11-012 citations
329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab
Regular and Young Investigator Award Abstracts2020-11-012 citations
A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)
Radiation Oncology2020-06-1220 citations
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Journal for ImmunoTherapy of Cancer2019-01-28100 citations
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Journal for ImmunoTherapy of Cancer2017-09-02156 citations
A phase I study of enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with nivolumab in tumors of epithelial origin.
Journal of Clinical Oncology2017-05-202 citations
A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I.
Journal of Clinical Oncology2016-05-202 citations
A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.
Journal of Clinical Oncology2015-05-203 citations